Four Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Novartis (NYSE:NVS) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Novartis manufactures pharmaceutical and consumer healthcare products. At present, the stock has a dividend yield of 2.5%. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Mylan (NASDAQ:MYL) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Mylan is a global generic and specialty pharmaceuticals company. The stock price has risen 6.6% over the past month, better than the 5.5% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MYL stock.
Pacira Pharmaceuticals (NASDAQ:PCRX) earns a A this week, jumping up from last week’s grade of B. Pacira Pharmaceuticals is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of PCRX stock.
This week, Acura Pharmaceuticals (NASDAQ:ACUR) pushes up from a C to a B rating. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.